Company: EVGN
Filing Date: 2025-03-28
Form Type: POS AM
Source: 0001178913-25-001096
Chunk: 4

Company: Evogene Ltd.
Filing Date: 2025-03-28
Form: POS AM
Chunk 4
---
 Selling Shareholder has not, authorized anyone to give any information or to make any representations other than those contained in this prospectus. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is not an offer to sell, and it is not soliciting an offer to buy, (1) any securities other than our ordinary shares or (2) our ordinary shares in any circumstances in which such an offer or solicitation is unlawful. The information contained in this prospectus may change after the date of this prospectus. Do not assume after the date of this prospectus that the information contained in this prospectus is still correct. Information contained on our website, www.evogene.com, does not constitute part of this prospectus. As used herein, and unless the context suggests otherwise, the following terms have the following meanings:

| • | “Evogene,” “we,” “us,” “our,” “our company” and “the Company” refer to Evogene Ltd. and its consolidated subsidiaries, consisting of: Ag Plenus Ltd., or Ag Plenus; 
 Biomica Ltd., or Biomica; Casterra Ag Ltd., or Casterra; Lavie Bio Ltd., or Lavie Bio; and their consolidated subsidiaries.                                         |
| • | “Articles” refers to our amended and restated articles of association, as currently in effect;                                                                      |
| • | “Companies Law” refers to the Israeli Companies Law, 5759-1999;                                                                                                     |
| • | “dollar” and “$” refer to U.S. dollars, the lawful currency of the United States;                                                                                   |
| • | “Exchange Act” refers to the United States Securities Exchange Act of 1934, as amended;                                                                             |
| • | “Nasdaq” refers to the Nasdaq Capital Market;                                                                                                                       |
| • | “NIS” refer to New Israeli Shekels, the lawful currency of the State of Israel;                                                                                     |
| • | “ordinary shares” or “shares” refer to our ordinary shares, par value NIS 0.20 per share;                                                                           |

| • | “private placement” refers to the private placement in which we sold 1,692,308 Series A warrants and 1,692,308 Series B warrants to the Selling Shareholder, which was 
 completed pursuant to the Securities Purchase Agreement on August 26, 2024;                                                                                            |
| • | “registered direct